Genesis Molecular AI

Genesis Therapeutics have developed an advanced molecular AI platform that accelerates the development of critical new medicines.

Genesis Molecular AI (formerly Genesis Therapeutics) develops AI technology for small-molecule drug discovery. Its GEMS platform combines foundation models, generative AI, molecular simulation, and computational chemistry to generate drug candidates, predict molecular properties, evaluate protein-ligand interactions, and guide lead optimization.

Exscientia

Exscientia has developed a functional precision oncology platform that successfully guides treatment selection and improves patient outcomes

Exscientia develops AI-driven drug discovery technology that uses generative design, machine learning, active learning, and automated analysis to design and prioritize potential drug molecules. Its platform combines computational models with laboratory experiments to explore chemical space and advance drug candidates for complex diseases.

Evaxion Biotech

Evaxion Biotech is a clinical-stage biotech company on a mission to decode the human immune system to develop effective immunotherapies.

Evaxion Biotech develops AI-powered immunology technologies for discovering vaccine targets and designing personalized vaccines and immunotherapies. Its AI-Immunology platform is focused on cancer and infectious diseases, supporting target discovery, vaccine design, and development.

Envisagenics

Envisagenics is a biotechnology company that has developed a unique platform called SpliceCore to identify, test, and validate drug targets.

Envisagenics develops AI-powered drug discovery technology focused on RNA splicing. Its SpliceCore platform analyzes large-scale RNA sequencing data to identify disease-specific therapeutic targets, with research focused on oncology and neurodegenerative diseases. The company also develops RNA therapeutics and partners with biopharmaceutical organizations to advance drug discovery.

AcuraStem

AcuraStem is a patient-based biotechnology company that is revolutionizing the way treatments are developed for neurodegenerative diseases.

AcuraStem is a biotechnology company developing treatments for neurodegenerative diseases, including ALS and frontotemporal dementia. Its iNeuroRx platform uses patient-derived disease models to study how these conditions develop and identify potential treatments. The company’s research includes antisense oligonucleotide therapies and targets such as UNC13A, SYF2, and PIKFYVE.

Verge Genomics

Verge Genomics has developed an advanced all-in-human AI-powered platform to expedite the process of discovering new drugs.

Verge Genomics, now operating as Verge Labs, develops AI systems that analyze human biological and patient data for neuroscience drug development. Its CONVERGE platform identifies potential drug targets, characterizes disease biology, identifies biomarkers, and helps drug developers select patient groups for clinical trials. The technology focuses on neurological diseases and uses multimodal genomic, proteomic, and clinical data to support drug research.

Tempus

Tempus is a techbio company that built the world’s largest library of clinical and molecular data and an OS to make that data accessible.

Tempus combines AI, genomic testing, clinical data, and machine learning to support precision medicine. Its technology helps healthcare providers analyze patient data, identify treatment options, match patients with clinical trials, and detect disease earlier. Tempus also works with pharmaceutical and biotechnology companies on drug discovery, biomarker research, clinical trials, companion diagnostics, and real-world data analysis.

Simulations Plus

Simulations Plus is a leading company in the field of drug discovery and development, providing innovative solutions to improve health.

Simulations Plus develops software and provides consulting services for pharmaceutical research and drug development. Its tools use AI, machine learning, molecular modeling, pharmacokinetic and pharmacodynamic simulations, and quantitative systems pharmacology to help scientists evaluate drug candidates, predict ADMET properties, model drug absorption and exposure, assess toxicity, and support clinical development.

Schrödinger

Schrödinger is a leading company in the field of drug discovery that is transforming the way therapeutics and materials are discovered.

Schrödinger develops computational software for discovering and designing molecules for drug development and materials science. Its platform combines physics-based molecular simulations, machine learning, and AI to predict molecular properties, screen compounds, optimize drug candidates, and study biological interactions. The company also provides tools for antibody design, protein modeling, materials research, molecular dynamics, and virtual screening.

PrecisionLife

PrecisionLife is a pioneering techbio company that is revolutionizing the field of drug discovery and personalized treatment selection.

PrecisionLife uses AI, genomic data, and combinatorial analytics to understand the biological mechanisms behind complex chronic diseases. Its platform identifies disease subgroups, discovers drug targets and biomarkers, predicts treatment response, and supports precision drug discovery and clinical trial design. The company also develops diagnostic tools for earlier disease risk assessment and more personalized treatment decisions.